Philips has reported a loss from operations of 824 million euros for the first quarter of 2024, due to a heavy provision announced today to settle a dispute involving its US subsidiary Respironics.

On an adjusted basis, the Dutch medical technology group posted an EBITA margin of 9.4% on sales of 4.1 billion euros, up 2.4% on a like-for-like basis thanks to both mature and growth regions.

This growth was achieved despite a decline in China, where the market is impacted by anti-corruption measures and depressed household demand. Because of this country, Philips' order intake fell by 3.8% on a comparable basis.

Philips nevertheless confirms its target of an adjusted EBITA margin of 11-11.5% and like-for-like sales growth of 3-5% for 2024, as well as its confidence in its 2025 plan "while recognizing that uncertainties remain".

Copyright (c) 2024 CercleFinance.com. All rights reserved.